Cardiome Announces Positive Data From BRINAVESS Study - Quick Facts

(RTTNews) - Cardiome Pharma Corp. (CRME), Monday announced publication of positive data from an observational, retrospective study, that included 251 recent-onset atrial fibrillation or AF patients who received 355 BRINAVESS treatments during the period between January 15 2011 and April 15 2013. The results are published in the October 2013 issue of The European Journal of Cardiovascular Medicine. Conversion efficacy was 76 percent in patients with AF duration less than 10 hours, and the median time spent in the ER for patients who converted on BRINAVESS was 6.5 hours.

"Skåne University Hospital developed a "fast-track" AF program in the emergency room where patients with short duration AF were promptly treated with BRINAVESS, which likely contributed to the higher efficacy seen in this setting compared to the ACT and AVRO clinical trials," stated Dr. Steen Juul-Möller, the study's Principal Investigator and Cardiome's Medical Director."